AQR Capital Management
NMRA icon

AQR Capital Management’s Neumora Therapeutics NMRA Stock Holding History

AQR Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Sell
13,613
-42,382
-76% -$80.7K ﹤0.01% 3889
2026
Q1 		$109K Sell
55,995
-38,175
-41% -$98.9K ﹤0.01% 3677
2025
Q4 		$169K Sell
94,170
-113,487
-55% -$249K ﹤0.01% 3392
2025
Q3 		$378K Sell
207,657
-568,415
-73% -$919K ﹤0.01% 2955
2025
Q2 		$569K Buy
776,072
+313,469
+68% +$237K ﹤0.01% 2544
2025
Q1 		$463K Buy
+462,603
New +$792K ﹤0.01% 2471

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's NMRA Position: Q2 2026 in Review

AQR Capital Management reduced its Neumora Therapeutics (NMRA) stake by 76% in Q2 2026, selling an estimated $80.7K and leaving 13,613 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3889.

AQR Capital Management first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. The position peaked at $569K in Q2 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • AQR Capital Management held 13,613 shares of Neumora Therapeutics worth $23.1K as of Q2 2026.
  • AQR Capital Management sold 42,382 Neumora Therapeutics shares in Q2 2026, an estimated $80.7K.
  • Neumora Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3889 holding.
  • AQR Capital Management first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • AQR Capital Management's Neumora Therapeutics position peaked at $569K in Q2 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.